PROLONG is a clinical research study evaluating Ebopiprant (OBE022) in pregnant women with threatened spontaneous preterm labour. Status: recruiting
Category: Content
This category defines content that can be used throughout the website. So for example an article, a report, a file,… i.e. a press release can be displayed on the “press release” page but the newest press release is also displayed on the homepage.
Implant 4: Nolasiban in IVF
IMPLANT 4 is a clinical research study evaluating nolasiban in women undergoing IVF. Women receive a single administration of 900…
Edelweiss 3: Endometriosis Associated Pain
Edelweiss 3 is a clinical research study evaluating linzagolix in women with endometriosis associated pain. This study is treating women…
Primrose 1 & 2: Heavy Menstrual Bleeding due to Uterine Fibroids
Primrose 1 & 2 are clinical research studies evaluating linzagolix in women with heavy menstrual bleeding due to uterine fibroids….
Investor relations
IR@obseva.ch
Media
contact@obseva.ch
ObsEva Switzerland Office
Chemin des Aulx,12 1228, Plan-Les-Ouates, Geneva, Switzerland +41 (0)22 552 3840 contact@obseva.ch
Robert Taylor, MD, PhD
Member
ObsEva Scientific Advisory Board
Hugh Taylor, MD
Member
ObsEva Scientific Advisory Board
Jacques Donnez, MD, PhD
Member
ObsEva Scientific Advisory Board